---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-25-000063"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:12:34.074762+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Xencor appoints Raymond Deshaies, Ph.D. to board of directors

## Summary
- Dr. Deshaies is a former SVP of global research at Amgen with 25+ years in biotech.
- Received initial option grant with $550,000 Black-Scholes value; vests over 3 years.
- Also receives $50,000 annual cash retainer; standard indemnification agreement.
- Deshaies co-founded Proteolix (discovered carfilzomib/KYPROLIS) and Cleave Biosciences.

## SEC filing metadata
- accession: 0001326732-25-000063
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000063/0001326732-25-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000063/xncr-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-25-000063
- JSON: https://secwatch.observer/filing/0001326732-25-000063.json
- Plain text: https://secwatch.observer/filing/0001326732-25-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.